Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04000061

Heart Failure-USB: Prediction and Progression

This retrospective cohort study is to identify triggers of heart failure (HF) development and drivers of HF progression as well as the underlying cardiac disease (phenotype) to identify patients at risk and predict the clinical course of the disease. Data of patients who were hospitalized during the years 2010-2023 with acute coronary syndrome (ACS) and/ or with acute heart failure (AHF) will be collected and analyzed. In a subgroup cohort efficacy and safety of digoxin in patients with acute heart failure triggered by tachyarrhythmia will be evaluated.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acute Heart Failure Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Heart Failure Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cardiology, University Hospital Basel

Basel, 4031, Switzerland

Location status: Recruiting

Location contact

Christian Mueller, Prof. Dr.

CONTACT

[email protected]

+41 61 32 86 549

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients hospitalized with a primary diagnosis of ACS
  • Patients hospitalized with a primary or secondary diagnosis of AHF

Exclusion criteria

  • Existence of a documented statement of the patient against the scientific use of clinical data

Treatment and study plan

medical chart review

Other

data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations

data generated by direct IT export

Other

data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data

Primary outcomes

  1. number of all-cause death

    Time frame: 1 to 8 years after hospitalization

    number of all-cause death in patients hospitalized with ACS and AHF during the years 2010-2023.

  2. number of HF hospitalizations

    Time frame: 1 to 8 years after hospitalization

    number of new HF hospitalizations in patients hospitalized with ACS and AHF during the years 2010-2023

  3. number of cardiovascular death

    Time frame: 1 to 8 years after hospitalization

    number of cardiovascular death in patients hospitalized with ACS and AHF

  4. number of cardiovascular hospitalizations

    Time frame: 1 to 8 years after hospitalization

    number of cardiovascular hospitalizations

Study contacts

Contact information is provided by the study sponsor or research team.

Christian Müller, Prof. Dr.

CONTACT

[email protected]

0041 6132 86 549

Fiona Nafaa, MD

CONTACT

[email protected]

+41 61 32 87747

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Jun 27, 2019
Registry last updated
Apr 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.